Sign In
Buy AUPH
$15.67
+0.280 (+1.82%)
At Close: Jun 03, 2026
Aurinia Pharmaceuticals Inc. - Special Call
09:35am, Monday, 30'th Jun 2025
Presentation Operator MessageOperator (Operator)Good morning, and welcome to Aurinia's Aritinercept Phase I Study Results Conference Call. [Operator Instructions]
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
06:00am, Monday, 30'th Jun 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200).
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
05:00pm, Sunday, 29'th Jun 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025.
Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?
10:01am, Friday, 27'th Jun 2025
Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Aurinia shares rise ahead of key autoimmune therapy data
02:26pm, Thursday, 26'th Jun 2025
Shares of Aurinia Pharmaceuticals (TSX:AUP)(NASDAQ:AUPH) jumped 6.8% to $8.57 on Thursday afternoon as investors looked ahead to the company's first clinical data update for its experimental autoimmu
Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?
09:51am, Friday, 30'th May 2025
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
06:00am, Thursday, 22'nd May 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis.
Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance
12:56pm, Monday, 12'th May 2025
Aurinia Pharmaceuticals Inc. AUPH reported first-quarter earnings of 16 cents per share, compared to a loss of 7 cents a year ago. This beat the consensus of 10 cents.
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2025 Earnings Call Transcript
11:04am, Monday, 12'th May 2025
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Andrea Christopher - Corporate Communications and IR Peter Greenleaf - Preside
Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates
08:10am, Monday, 12'th May 2025
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.03 per share a year ago.
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
06:00am, Monday, 12'th May 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025.
Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025
06:00am, Monday, 05'th May 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025.
Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
06:00am, Wednesday, 30'th Apr 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Glass Lewis recommends that Aurinia Shareholders vote “FOR” all proposals at 2025 Annual General Meeting.
ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
06:00am, Tuesday, 29'th Apr 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--ISS recommends that Aurinia Shareholders vote “FOR” all proposals at 2025 Annual General Meeting.
Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth
10:54am, Saturday, 26'th Apr 2025
AUPH has seen some management changes, but activist investors demand more despite steady Lupkynis sales growth. The first quarter was strong in terms of sales in 2023 and 2024, and upcoming Q1 '25 ear
